LONGEVA.

Cagrilintide: adverse events and evidence limits

A 26-week subcutaneous cagrilintide trial enrolled adults without diabetes with obesity, or overweight plus hypertension or dyslipidemia. Nausea, constipation, diarrhea and administration-site reactions occurred. [1]

Results span distinct study doses, rather than one reaction frequency. This abstract does not establish catalog-reagent safety. [1]

What the studies reported

EffectModel or participantsHow often or as describedSource
NauseaAdults without diabetes with obesity, or overweight plus hypertension or dyslipidemia, subcutaneous, 26 weeksReported; there is no single frequency — results span distinct study doses[1]
ConstipationThe same participantsReported; no single frequency — results span distinct doses[1]
DiarrheaThe same participantsReported; no single frequency — results span distinct doses[1]
Administration-site reactionsThe same participantsReported; no single frequency — results span distinct doses[1]

References

  1. David C W Lau et al. (2021). Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial https://doi.org/10.1016/S0140-6736(21)01751-7.